AgomAb Therapeutics (NASDAQ:AGMB) Releases Quarterly Earnings Results

AgomAb Therapeutics (NASDAQ:AGMB) announced its quarterly earnings results on Thursday. The company reported ($0.46) earnings per share (EPS) for the quarter, FiscalAI reports.

AgomAb Therapeutics Stock Down 5.7%

NASDAQ AGMB opened at $13.50 on Friday. AgomAb Therapeutics has a 52 week low of $8.75 and a 52 week high of $17.82. The company’s 50-day simple moving average is $12.18. The company has a quick ratio of 6.52, a current ratio of 6.52 and a debt-to-equity ratio of 0.01.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. HC Wainwright assumed coverage on shares of AgomAb Therapeutics in a research report on Monday, June 22nd. They set a “buy” rating and a $35.00 price objective on the stock. B. Riley Financial started coverage on AgomAb Therapeutics in a report on Thursday, July 23rd. They set a “buy” rating and a $34.00 price target for the company. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, AgomAb Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $33.00.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.